预计结直肠癌治疗市场规模将从 2024 年的 199.3 亿美元增至 2031 年的 247.4 亿美元。预计 2025 年至 2031 年期间该市场的复合年增长率为 3.2%。
结直肠癌治疗市场分析
结直肠癌病例的不断增长以及靶向治疗和免疫治疗的不断进步,推动了结直肠癌治疗的应用。结直肠癌治疗根据癌症的分期和部位采用多种疗法。早期患者通常通过手术切除肿瘤。在晚期患者中,治疗可能包括化疗、放疗以及针对具有特定基因标记的肿瘤的靶向治疗或免疫治疗。对于转移性病例,全身治疗有助于控制疾病扩散。个性化治疗方案基于分子谱分析制定。支持性治疗则针对症状、营养和生活质量。
监管加速和对新疗法的支持为结直肠癌治疗市场提供了重大机遇,推动了市场增长。
结直肠癌治疗市场概况
预计北美将占据结直肠癌治疗市场的最大份额,而亚太地区预计在预测期内将实现显著的复合年增长率。亚太地区的结直肠癌治疗市场正在快速增长。该地区包括中国、日本、印度、韩国、澳大利亚等主要国家以及更广泛的亚太地区,每个国家都为市场扩张做出了贡献。北美,尤其是美国,结直肠癌的发病率很高。此外,大量老年人口也面临着更高的患病风险。结直肠癌病例的不断增加刺激了对先进疗法和治疗方案的需求。
结直肠癌病例的不断增加,刺激了对先进疗法和治疗方案的需求。该地区的技术进步和经济高效的生产模式,使制药公司能够以具有竞争力的价格生产高效药物,从而进一步提升其市场地位。
政府机构正在通过实施亲民的报销政策和其他医疗保健举措,使结直肠癌治疗变得触手可及,从而为结直肠癌治疗提供令人满意的费用覆盖。
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
结直肠癌治疗市场:

- 获取此报告的顶级关键市场趋势。此免费样品将包括数据分析,从市场趋势到估计和预测。
结直肠癌治疗市场驱动因素和机遇
市场驱动因素:
结直肠癌病例数量不断增加:
结直肠癌病例数量的增加是由人口趋势、生活方式的改变以及早发疾病模式的变化共同推动的,这些都反映在最近的流行病学统计数据和科学发展中。靶向治疗和免疫治疗的不断进步:
结直肠癌治疗市场进步的核心驱动力是靶向免疫疗法的显著进步,从根本上重塑了特定患者群体的治疗结果并扩大了未来的治疗可能性。精准医疗的蓬勃发展:
许多新型结直肠癌疗法,尤其是生物制剂和细胞疗法,价格高昂。这加剧了人们对负担能力的担忧,给公共卫生预算带来了压力,并造成了可及性差异。付款人和政府越来越多地评估基于价值的定价,引发了关于定价透明度、报销模式和全球成本控制政策的争论。
市场机会:
监管加速和对新疗法的支持:
结直肠癌治疗领域正经历着巨大的机遇,这得益于积极的监管加速和对新疗法的支持,重塑了治疗渠道、创新和患者结果。
新兴经济体的扩张:
由于结直肠癌病例数量和认知度不断增加,亚太、拉丁美洲和非洲的几个国家为结直肠癌治疗市场提供了增长机会。医疗旅游的兴起:
中国、印度、印度尼西亚、巴西和墨西哥等发展中国家的医疗旅游业日益繁荣,为游客提供了价格实惠的先进护理和治疗,价格比美国和欧洲国家低 30% 至 80%。增加政府和私人组织的支持:
一些政府和私人组织增加了对结直肠癌治疗研发的资金投入,从而促进了创新药物和疗法的开发。
技术进步
该地区的技术进步和具有成本效益的制造使公司能够以具有竞争力的价格生产创新药物,从而进一步增强其市场占有率。
结直肠癌治疗市场报告细分分析
为了更清晰地了解结直肠癌治疗市场运作方式、增长潜力和最新趋势,我们将市场细分为多个细分领域。以下是大多数行业报告中使用的标准细分方法:
按治疗:
外科手术:
手术仍然是局部性和晚期结直肠癌的基石治疗方法,机器人辅助和腹腔镜手术等创新可以改善治疗效果并缩短恢复时间。化疗:
化疗在全球结直肠癌治疗市场中占有相当大的份额,这得益于其长期以来作为治疗早期和晚期结直肠恶性肿瘤的一线全身治疗的作用。
靶向治疗:
靶向药物通过破坏或减缓癌细胞生长来抑制癌细胞生长。靶向治疗与传统化疗联合使用。免疫疗法:
免疫疗法利用个体的免疫系统有效识别并摧毁癌细胞。它通常针对人体免疫系统中的特定蛋白质,以增强免疫反应。其他治疗类型:
基因治疗、放射治疗和表观遗传治疗是结直肠癌治疗中最具创新性和最有前景的方法。
按年龄组:
49岁以下:
CRC 传统上被认为是老年人的疾病,但最近的数据显示,年轻人群中 CRC 的发病率呈上升趋势,令人担忧。针对年轻 CRC 患者的治疗方法正在不断改进,重点在于最大限度地减少长期副作用并提高生活质量。50至64岁:
结直肠癌患者群体正日益年轻化,50-64 岁年龄段人群在新发病例中占据了相当大的比例。 结直肠癌患者群体正日益年轻化,50-64 岁年龄段人群在新发病例中占据了相当大的比例。65岁以上:
随着全球人口老龄化,65岁及以上人口的比例正在显著上升。根据世界卫生组织的数据,到2030年,全球每6人中就有1人年龄在60岁或以上,其中80岁以上年龄段的人口增长速度最快。由于年龄是结直肠癌最重要的单一风险因素——约75%的病例发生在65岁以上的人群中——这种人口结构的变化直接扩大了需要治疗的患者群体。
按最终用户:
- 医院
- 专科诊所
- 家庭护理
- 其他的
按地域划分:
- 北美
- 欧洲
- 亚太地区
- 拉美
- 中东和非洲
北美结直肠癌治疗市场预计将占据相当大的市场份额。结直肠癌患病率的上升以及市场参与者的业务扩张战略可能会推动市场的发展。
结直肠癌治疗市场区域洞察
Insight Partners 的分析师已详尽阐述了预测期内影响结直肠癌治疗市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的结直肠癌治疗市场细分和地域分布。
结直肠癌治疗市场报告范围
报告属性 | 细节 |
---|---|
2024年的市场规模 | 199.3亿美元 |
2031年的市场规模 | 247.4亿美元 |
全球复合年增长率(2025-2031) | 3.2% |
史料 | 2021-2023 |
预测期 | 2025-2031 |
涵盖的领域 | 按治疗
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
结直肠癌治疗市场参与者密度:了解其对业务动态的影响
结直肠癌治疗市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求的驱动因素包括消费者偏好的转变、技术进步以及对产品优势的认知度的提升。随着需求的增长,企业正在扩展产品线,不断创新以满足消费者需求,并抓住新兴趋势,从而进一步推动市场增长。

- 获取结直肠癌治疗市场顶级关键参与者概览
结直肠癌治疗市场份额(按地区)分析
预计未来几年亚太地区将增长最快。拉丁美洲、中东和非洲等新兴市场也为结直肠癌治疗提供商提供了许多尚未开发的扩张机会。
各地区结直肠癌治疗市场的增长情况各不相同。这主要受多种因素影响,例如结直肠癌病例的增加、靶向疗法和免疫疗法的不断进步,以及创新肿瘤药物的日益普及。以下是各地区市场份额和趋势的总结:
1. 北美
市场份额:
占据全球市场的很大份额关键驱动因素:
- 结直肠癌病例不断增加
- 靶向治疗和免疫治疗的不断进步
- 个性化医疗蓬勃发展
趋势:
结直肠癌治疗药物制造商采用有机和无机策略。
2.欧洲
市场份额:
由于早期采用数字商务而占据相当大的份额关键驱动因素:
- 结直肠癌发病率上升
- 政府对结直肠癌治疗的严格监管
趋势:
结直肠癌治疗的技术进步
3. 亚太地区
市场份额:
增长最快的地区,市场份额逐年上升关键驱动因素:
- 在政府加大公共卫生投入的支持下,医疗基础设施得到快速改善。
- 公众和各机构对结直肠癌治疗的认识不断提高。
趋势:
医疗旅游兴起
4.南美洲和中美洲
市场份额:
市场稳步增长关键驱动因素:
- 癌症病例不断增加
- 药品进口增加
趋势:
医疗旅游兴起
5.中东和非洲
市场份额:
虽然规模小,但增长迅速关键驱动因素:
- 扩大医疗基础设施
- 医疗保健机构对结直肠癌治疗的认识不断提高
趋势:
政府提高结直肠癌治疗意识的举措
结直肠癌治疗市场参与者密度:了解其对业务动态的影响
市场密度高,竞争激烈
由于罗氏、辉瑞、赛诺菲、默克、百时美施贵宝、安进和礼来等老牌企业的存在,竞争十分激烈。Novugen Pharma(马来西亚)和 Kalbe Farma(亚太地区)等区域性和利基供应商也加剧了不同地区的竞争格局。
这种激烈的竞争促使公司通过提供以下产品脱颖而出:
- 高级产品
- 定制和可持续解决方案等增值服务
- 竞争性定价模型
- 遵守监管指南
机遇与战略举措
- 专注于更有效、更有针对性的癌症疗法。癌症发病率的上升以及对先进疗法的需求,推动了研发投入的激增。
- 公司正在转向下一代肿瘤治疗和精准治疗,以解决监管和消费者对癌症治疗的担忧
- 专注于直接面向消费者的渠道,并加强电子商务平台的使用,以接触更广泛的客户群体。
在结直肠癌治疗市场运营的主要公司有:
- 拜耳公司
- 百时美施贵宝公司
- 安进公司
- 礼来公司
- 基因泰克公司(F. Hoffmann-La Roche Ltd)
- 辉瑞公司
- 武田药品工业株式会社
- 梯瓦制药工业有限公司
- 再生元制药公司
- 大冢控股株式会社
免责声明:以上列出的公司没有按照任何特定顺序排列。
研究过程中分析的其他公司:
- 因塞特公司
- 吉利德科学公司
- 第一三共株式会社
- 鲁宾制药公司
- 益普生
- 勃林格殷格翰
- 格兰马克制药公司
- 吉利德科学
- 奥登生命科学
- Cytogen Pharmaceuticals印度私人有限公司
- 蓝鸟生物
- 百奥康有限公司
- 百济神州
- 阿森迪斯制药
- 太阳制药工业
- 克洛维斯肿瘤学
- 西普拉有限公司
- 蓝图医药
结直肠癌治疗市场新闻及最新进展
- Glenmark 将在印度推出 DCGI 批准的抗癌药物
- 武田制药的 FRUZAQLA(呋喹替尼)获得美国 FDA 批准,用于治疗先前接受过治疗的转移性结直肠癌。
- Guardant Health 的 Shield 血液检测获 FDA 批准作为主要筛查选项,为医疗保险报销扫清道路,开启结直肠癌筛查新时代
结直肠癌治疗市场报告覆盖范围和交付成果
《结直肠癌治疗市场规模和预测(2021-2031)》报告对以下领域进行了详细的市场分析:
- 结直肠癌治疗市场规模及全球、区域和国家层面所有主要细分市场的预测
- 结直肠癌治疗市场趋势以及市场动态,例如驱动因素、限制因素和关键机遇
- 详细的 PEST 和 SWOT 分析
- 结直肠癌治疗市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
- 行业格局和竞争分析,包括市场集中度、热图分析、知名参与者以及结直肠癌治疗市场的最新发展
- 详细的公司简介
- 历史分析(2 年)、基准年、预测(7 年)及复合年增长率
- PEST 和 SWOT 分析
- 市场规模价值/数量 - 全球、区域、国家
- 行业和竞争格局
- Excel 数据集


- Retinal Imaging Devices Market
- Mail Order Pharmacy Market
- Machine Condition Monitoring Market
- HVAC Sensors Market
- Aerospace Forging Market
- Hair Wig Market
- Passport Reader Market
- Digital Language Learning Market
- Health Economics and Outcome Research (HEOR) Services Market
- Batter and Breader Premixes Market

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
常见问题
North America dominated the market in 2024.
The growing number of colorectal cancer cases and increasing advancements in targeted and immunotherapies are among the noteworthy factors contributing to the market growth.
The colorectal cancer treatment market is estimated to register a CAGR of 3.2% during the forecast period.
Bristol-Myers Squibb Co., Bayer AG, Amgen Inc., Eli Lilly and Co., Genentech Inc. (F. Hoffmann-La Roche Ltd), Pfizer Inc., Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., and Otsuka Holdings Co., Ltd. are among the key players operating in the colorectal cancer treatment market.
The colorectal cancer treatment market is estimated to reach US$ 24.74 billion by 2031.
The List of Companies - Colorectal Cancer Treatment Market
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd (Genentech)
- Bayer AG
- Eli Lilly and Co.
- Pfizer Inc.
- Takeda Pharmaceutical Company
- Bristol-Myers Squibb Co.
- Teva Pharmaceutical Industries Ltd
- Regeneron Pharmaceuticals
- Otsuka Holdings Co Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.